Cargando…
Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion
AIM: To assess cholesterol screening of children with Type 1 diabetes by diabetes professionals using a survey of current practice, given that National Institute of Health and Care Excellence guidelines on childhood Type 1 diabetes do not recommend cholesterol screening, yet the National Paediatric...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485173/ https://www.ncbi.nlm.nih.gov/pubmed/28144991 http://dx.doi.org/10.1111/dme.13322 |
_version_ | 1783246008474402816 |
---|---|
author | Candler, T. Mahmoud, O. Edge, J. Hamilton‐Shield, J. |
author_facet | Candler, T. Mahmoud, O. Edge, J. Hamilton‐Shield, J. |
author_sort | Candler, T. |
collection | PubMed |
description | AIM: To assess cholesterol screening of children with Type 1 diabetes by diabetes professionals using a survey of current practice, given that National Institute of Health and Care Excellence guidelines on childhood Type 1 diabetes do not recommend cholesterol screening, yet the National Paediatric Diabetes Audit has an annual cholesterol measure (> 12 years) as a key outcome indicator. METHODS: An online survey was sent to 280 members of the Association of Children's Diabetes Clinicians to assess cholesterol screening practice in children. RESULTS: A total of 87 diabetes professionals (31%) responded. The results showed that 94% of respondents measured cholesterol, 33% did this annually on all children, and 7% measured fasting cholesterol. A total of 63% used no guidelines to decide treatment or further investigation. The definition of ‘high’ cholesterol varied from > 4.5 to > 8 mmol/l, with 40% giving no response or specific level. Only 14% of clinicians had started statin therapy in their diabetes clinic in the previous 5 years. CONCLUSION: Whilst the majority of diabetes professionals measured cholesterol in children with Type 1 diabetes, there was marked variability in sampling, in children screened and in action taken if levels were considered abnormal. It is debatable whether cholesterol measures should be undertaken, certainly more than once, and whether cholesterol level should feature as a key outcome in the national audit in future. |
format | Online Article Text |
id | pubmed-5485173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54851732017-07-11 Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion Candler, T. Mahmoud, O. Edge, J. Hamilton‐Shield, J. Diabet Med Research Articles AIM: To assess cholesterol screening of children with Type 1 diabetes by diabetes professionals using a survey of current practice, given that National Institute of Health and Care Excellence guidelines on childhood Type 1 diabetes do not recommend cholesterol screening, yet the National Paediatric Diabetes Audit has an annual cholesterol measure (> 12 years) as a key outcome indicator. METHODS: An online survey was sent to 280 members of the Association of Children's Diabetes Clinicians to assess cholesterol screening practice in children. RESULTS: A total of 87 diabetes professionals (31%) responded. The results showed that 94% of respondents measured cholesterol, 33% did this annually on all children, and 7% measured fasting cholesterol. A total of 63% used no guidelines to decide treatment or further investigation. The definition of ‘high’ cholesterol varied from > 4.5 to > 8 mmol/l, with 40% giving no response or specific level. Only 14% of clinicians had started statin therapy in their diabetes clinic in the previous 5 years. CONCLUSION: Whilst the majority of diabetes professionals measured cholesterol in children with Type 1 diabetes, there was marked variability in sampling, in children screened and in action taken if levels were considered abnormal. It is debatable whether cholesterol measures should be undertaken, certainly more than once, and whether cholesterol level should feature as a key outcome in the national audit in future. John Wiley and Sons Inc. 2017-03-08 2017-07 /pmc/articles/PMC5485173/ /pubmed/28144991 http://dx.doi.org/10.1111/dme.13322 Text en © 2017 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Articles Candler, T. Mahmoud, O. Edge, J. Hamilton‐Shield, J. Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion |
title | Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion |
title_full | Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion |
title_fullStr | Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion |
title_full_unstemmed | Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion |
title_short | Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion |
title_sort | hypercholesterolaemia screening in type 1 diabetes: a difference of opinion |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485173/ https://www.ncbi.nlm.nih.gov/pubmed/28144991 http://dx.doi.org/10.1111/dme.13322 |
work_keys_str_mv | AT candlert hypercholesterolaemiascreeningintype1diabetesadifferenceofopinion AT mahmoudo hypercholesterolaemiascreeningintype1diabetesadifferenceofopinion AT edgej hypercholesterolaemiascreeningintype1diabetesadifferenceofopinion AT hamiltonshieldj hypercholesterolaemiascreeningintype1diabetesadifferenceofopinion |